Los Gatos, California
•
Today
Akura Medical, a Shifamed portfolio company, is advancing a differentiated platform for the treatment of venous thromboembolism (VTE), which affects up to 900,000 Americans each year. The company recently received US IDE approval for its QUADRA-PE study evaluating the Katana Thrombectomy System in acute pulmonary embolism patients. In parallel, Akura Medical is developing NavIQ , a software platform that transforms CT angiograms into 3D pulmonary vascular models to enhance visualization, proced
Full-time
USD 130,000.00 - 160,000.00 per year















